HIPAA-compliant · Same-day admissions available
Robin Campbell, LMFT, PHD Across the country, health professionals are rethinking how to improve recovery for individuals facing opioid use disorder (OUD) and drug or alcohol dependence.
Maverick
Clinical Editorial Team
Across the country, health professionals are rethinking how to improve recovery for individuals facing opioid use disorder (OUD) and drug or alcohol dependence. New evidence suggests that adjusting buprenorphine dose and delivery may improve outcomes for patients treated with agonist opioids or those with high opioid tolerance. Research highlights the importance of monthly maintenance doses, such as those provided by extended-release formulations, to optimize patient recovery and safety.
Although opioid withdrawal, injection site reactions, and treatment access remain ongoing challenges, research points to clinically meaningful improvements for patients receiving medication treatment within a complete care plan. Notably, adherence to eight monthly maintenance doses has been shown to sustain treatment gains and reduce relapse risk. However, while some studies show clinical improvements, not all results reach a statistically significant advantage for primary endpoints. As the Mental Health Services Administration reviews emerging data, the focus continues to shift toward smarter dosing, the need to monitor patients closely for adverse effects and treatment adherence, and stronger recovery stability. Regular assessment of liver function tests is essential for detecting potential hepatic side effects during treatment.
This month’s newsletter highlights how advances in opioid therapy may open the door to safer, more effective recovery—particularly for those with severe opioid use disorder or intense fentanyl use patterns—without giving away all the answers just yet.
Opioid use disorder (OUD) is a chronic disease that disrupts the brain’s ability to regulate essential functions, leading to patterns of opioid use with serious health, social, and emotional consequences. Individuals with OUD may struggle with opioid withdrawal, high opioid tolerance, and a heightened risk of overdose or neonatal opioid withdrawal syndrome, making it a significant public health concern that affects not only individuals but also their families and communities.
Treating OUD requires a comprehensive approach that combines medication treatment—such as buprenorphine—with behavioral therapies and ongoing support. Buprenorphine, a Schedule III controlled substance, is a cornerstone of modern OUD care. Available in both sublingual and extended-release injectable forms, it helps reduce cravings and withdrawal symptoms, supporting patients as they work toward opioid abstinence and improved health. For those with severe opioid use disorder or high opioid tolerance, high dose buprenorphine has demonstrated clinically meaningful improvements in treatment outcomes, including better retention in care and higher rates of opioid abstinence.
However, higher doses of buprenorphine require careful medical supervision. Patients must be closely monitored for potential risks, such as serious injection site reactions or life-threatening respiratory depression. Individualized dosing regimens and regular assessment of liver function and overall health are essential to ensure safety and maximize the benefits of treatment.
Improving OUD treatment access also means addressing the social determinants of health and systemic barriers that can prevent individuals from receiving effective care. Culturally appropriate interactive education, community outreach, and institutional support are vital for reaching underserved populations and ensuring that everyone has the opportunity to benefit from evidence-based treatment strategies.
Ongoing research is needed to refine dosing regimens, understand the long-term effects of high dose buprenorphine, and develop new approaches that further improve treatment outcomes. By working together—patients, providers, and communities—we can transform OUD care, reduce national drug overdose deaths, and help more individuals achieve lasting recovery.
Buprenorphine is a medication used to treat opioid use disorder by reducing cravings and withdrawal symptoms. It acts as a partial opioid agonist, meaning it activates the brain’s opioid receptors but with a ceiling effect that lowers overdose risk. This allows patients to feel stable without experiencing the intense highs or lows linked to opioid misuse. Patients typically have initiated treatment with a short-acting buprenorphine formulation before transitioning to extended-release options. When used in a structured treatment plan, buprenorphine helps individuals regain control over their recovery process. It supports clearer thinking, improved functioning, and greater engagement in therapy or daily responsibilities. Many treatment programs, including those at New Hope Healthcare Institute, use buprenorphine as part of a complete treatment plan that includes counseling and psychosocial support to promote lasting recovery.
High dose buprenorphine has been shown to significantly improve treatment outcomes for individuals struggling with opioid addiction. By providing stronger and longer-lasting control over withdrawal symptoms and cravings, it allows patients to maintain physical and emotional stability throughout recovery. This stability supports better participation in therapy and reduces the likelihood of relapse. Many patients have experienced clinically meaningful improvements in their recovery as a result of these benefits.
Research shows that patients on higher doses experience improved retention in treatment programs and lower rates of illicit opioid use, with high dose buprenorphine being associated with better treatment outcome measures. The consistent receptor activation in the brain helps balance mood, concentration, and motivation—key factors in long-term success. With proper medical supervision, high dose buprenorphine can be a safe and effective tool in achieving lasting recovery and rebuilding daily life.
Ongoing evaluation of clinical outcomes is essential to optimize therapy and ensure the best possible results for patients.
Buprenorphine is effective for various opioid dependencies by easing withdrawal and reducing cravings:
In some cases, buprenorphine may also be used to help treat pain in patients with opioid use disorder.
Finding the correct buprenorphine dosage is essential for achieving stable recovery and preventing relapse. Standard doses of 8 mg to 16 mg per day are effective for many, but research shows that \\higher doses—24 mg to 32 mg daily—\\provide stronger receptor coverage and longer-lasting relief for those with severe opioid dependence or fentanyl exposure. Dosing regimens led by patient needs, including increased or multiple dosing strategies, can improve outcomes, especially in challenging treatment settings.
Studies consistently link higher doses to improved treatment retention, fewer withdrawal symptoms, and reduced illicit opioid use. For individuals with high opioid dose consumption, high doses are often necessary to achieve significant reductions in opioid use and better recovery results. Patients on high dose buprenorphine often experience better mood balance, clearer focus, and increased engagement in therapy, which strengthens long-term recovery outcomes.
Clinicians are now moving away from rigid dosing limits, favoring individualized, medically supervised plans that match each patient’s needs. This flexible, evidence-based approach helps more people stay in treatment longer and maintain lasting recovery success. Individualized dosing regimens led to better retention and recovery, particularly for those with severe or high-risk opioid use.
Buprenorphine works by binding to the brain’s mu-opioid receptors, the same receptors affected by drugs like heroin or oxycodone. However, as a partial opioid agonist, it activates these receptors just enough to relieve cravings and withdrawal—without causing the intense euphoria or dangerous respiratory depression seen with full opioids. The degree of buprenorphine exposure, including plasma concentration levels, can influence the effectiveness of treatment and abstinence outcomes.
In the body, buprenorphine helps restore chemical balance disrupted by prolonged opioid use. It stabilizes mood, reduces stress responses, and supports normal brain function over time. By blocking the effects of other opioids, it also prevents misuse and helps individuals regain control of their physical and mental health during recovery.
Buprenorphine has a much lower addiction risk than opioids like heroin, oxycodone, or fentanyl. As a partial opioid agonist, it activates brain receptors mildly, preventing withdrawal without causing a euphoric “high.” Unlike full opioids or methadone, buprenorphine has a ceiling effect, meaning taking more doesn’t increase its impact. While mild dependence can develop, it’s medically managed and not the same as addiction. Drug dependence is a recognized clinical condition that is distinct from addiction, and it can occur with long-term use of medications like buprenorphine. When used as prescribed, buprenorphine supports recovery safely and effectively. Buprenorphine is also used in the management of drug and alcohol dependent cases.
High dose buprenorphine is showing strong results among individuals with severe or long-term opioid dependence, frequent relapse, or fentanyl exposure. These patients often need higher doses to maintain stability, control cravings, and prevent withdrawal. Patients dependent on opioids who exhibit high risk opioid use patterns, such as injection drug use or high fentanyl consumption, may require even higher doses and careful monitoring to achieve optimal outcomes.
Studies indicate that the prevalence of successful recovery increases when patients receive 24 mg to 32 mg daily, especially in structured treatment settings. High dose approaches are especially valuable in challenging treatment settings, where barriers like high fentanyl use or institutional obstacles complicate care. Programs using high dose approaches report higher retention rates and lower relapse compared to standard dosing.
As more providers recognize its effectiveness, high dose buprenorphine is becoming a leading choice for individuals who struggled with lower doses. With individualized care and medical oversight, these patients are achieving greater recovery stability and long-term success.
Short-Term Effects:
Common injection site reactions include pain, redness, and itching.
Long-Term Effects:
Providers should be prepared to manage emergent acute pain in patients receiving buprenorphine.
Mental health has a direct impact on recovery outcomes during buprenorphine treatment. Many patients face co-occurring disorders that can affect motivation, focus, and emotional balance if not treated together with addiction.
Common mental health issues linked to opioid use disorder include:
Integrated care that treats both addiction and mental health helps patients stay stable, reduce relapse risk, and build long-term recovery success.
High dose buprenorphine plays a key role in lowering relapse risk by keeping cravings and withdrawal symptoms under control. This steady balance allows patients to focus on recovery goals instead of managing constant discomfort or temptation to use opioids. Achieving an expected and treatable outcome is a key goal of high dose therapy, as it helps ensure that treatment results are both desirable and manageable for patients. When combined with counseling and structured support, higher doses can lead to stronger, longer-lasting recovery outcomes.
Discussing dosage adjustments with a licensed provider is an important step in achieving the right balance. Patients should share details about cravings, side effects, or emotional changes so providers can safely modify dosing as needed. Open communication ensures treatment remains both effective and personalized.
Support systems—such as family, peer recovery groups, and therapy—reinforce the progress made through medication-assisted treatment. These connections help patients stay motivated, manage stress, and maintain accountability. Together, medical supervision, proper dosing, and strong support networks form the foundation for sustained recovery success.
Access to buprenorphine treatment has improved across the U.S., but many people still face barriers such as provider shortages, insurance limits, or stigma around medication-assisted treatment. Expanding prescribing authority and increasing education for healthcare professionals are key steps in making this life-saving medication more available.
Even with wider access, medical supervision remains essential. A recent post hoc analysis found that injectable buprenorphine (300 mg) showed strong outcomes among individuals reporting pain reliever misuse, highlighting the need for clear warnings and precautions addiction guidance and better disease control strategies to overcome ongoing OUD treatment barriers. Each patient’s history, opioid use level, and co-occurring conditions must guide dosing and treatment planning. Individualized care ensures that buprenorphine is used safely and effectively, helping patients achieve stability while minimizing risks. Appropriate treatment approaches should be selected based on each patient’s unique circumstances to address specific barriers and support optimal outcomes. Combining expanded access with proper clinical oversight supports better recovery outcomes nationwide.
Many misconceptions exist about high dose buprenorphine. One myth is that higher doses are unsafe or addictive, but buprenorphine’s ceiling effect prevents overdose when used as prescribed.
Another false belief is that buprenorphine replaces one addiction with another. In truth, it stabilizes the brain, reduces cravings, and allows normal functioning without producing a “high.”
Some also think recovery shouldn’t involve medication, yet research shows medication-assisted treatment (MAT) greatly improves recovery rates. Understanding these facts helps reduce stigma and supports access to proven, effective care.
Medication-Assisted Treatment (MAT) combines FDA-approved medications like buprenorphine with behavioral therapy and counseling to treat opioid use disorder. This integrated approach helps stabilize brain chemistry, reduce cravings, and support long-term recovery by addressing both physical dependence and mental health needs.
Access to MAT has expanded, but insurance coverage and advocacy still play major roles in treatment availability. Many plans cover buprenorphine-based programs, though limits or prior authorizations may apply. Patients and providers often work together to navigate insurance policies, advocate for expanded coverage, and remove barriers to care. Ensuring accessible, affordable MAT allows more individuals to receive effective treatment and sustain lasting recovery.
It’s important to seek professional help if opioid use begins to interfere with daily responsibilities, relationships, or health. Warning signs include increasing tolerance, withdrawal symptoms, or failed attempts to quit. Early intervention with a qualified provider can prevent further harm and improve the chances of successful recovery.
Most insurance plans, including Medicaid and private providers, cover opioid treatment under mental and behavioral health services. Coverage may include medication-assisted treatment, therapy, and outpatient programs. Patients should contact their insurance provider or treatment center directly to confirm benefits and understand any copay or preauthorization requirements.
As treatment programs evolve, one message is clear—patients can achieve opioid abstinence and long-term recovery through evidence-based care, individualized dosing, and strong clinical oversight. With advances in buprenorphine extended release, higher maintenance dose studies, and ongoing clinical trials, new data are helping providers transform treatment strategies for this treated chronic disease. By continuing further research and offering culturally appropriate education, providers can help reduce national drug overdose deaths and deliver more clinically meaningful improvements across communities. The future of OUD treatment access lies in collaboration, precision, and compassion—moving beyond survival to lasting wellness.
At New Hope Healthcare, as an in-network provider we work with most insurance plans, such as:
If you or a loved one are struggling with mental health challenges or substance abuse, seeking treatment and emotional support is crucial. Consulting a doctor can provide the necessary support and guidance for your teen. Reach out to New Hope Healthcare today. Our team of compassionate professionals is here to support your journey towards lasting well-being. Effective medication management is a crucial part of the treatment process to ensure safety and success. Give us a call at 866-799-0806.
Visit SAMHSA for more information.
Yes. When prescribed and monitored by a licensed provider, high dose buprenorphine is safe and effective. Research shows it can reduce cravings, withdrawal symptoms, and relapse risk without increasing overdose danger.
Patients with severe opioid dependence, frequent relapse, or poor response to lower doses may benefit most. A provider evaluates medical history, current symptoms, and treatment goals before adjusting dosage.
Absolutely. Combining medication-assisted treatment (MAT) with counseling, peer support, and behavioral therapy improves long-term recovery outcomes and strengthens mental health stability.
High dose buprenorphine helps maintain consistent brain receptor activation, reducing cravings and withdrawal intensity. This stability supports better focus in therapy and longer treatment retention.
Possible side effects include nausea, constipation, headache, or drowsiness. These effects are usually mild and temporary when monitored by a healthcare provider during treatment.
Treatment duration varies. Some patients use high dose therapy short-term to stabilize recovery, while others continue long-term maintenance under medical supervision for sustained results.
](https://www.samhsa.gov/sites/default/files/quick-start-guide.pdf)
](https://www.nih.gov/news-events/news-releases/higher-doses-buprenorphine-may-improve-treatment-outcomes-people-opioid-use-disorder)
](https://nida.nih.gov/research-topics/medications-opioid-use-disorder)
](https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder)
In This Article
Tags
Clinically Reviewed by: Dr. Robin Campbell, LMFT, PHD If you are looking for help for parents of an adult child with addiction, you are not alone.
Clinically Reviewed by: Dr. Robin Campbell, LMFT, PHD Recovery does not happen alone, and finding the right support can make a lasting difference.
Clinically Reviewed by: Dr. Robin Campbell, LMFT, PHD Narcan has become an important part of overdose prevention as Tennessee communities face synthetic opioids and opioid dependence.
Clinically Reviewed by: Dr. Robin Campbell, LMFT, PHD Obsessive-compulsive disorder affects millions of people, yet many misconceptions still surround its symptoms, causes, and treatment.
Clinically Reviewed by: Dr. Robin Campbell, LMFT, PHD Many people wonder whether medications for alcohol use disorder can help them reduce alcohol consumption, manage cravings, or support long-term recovery.
Clinically Reviewed by: Dr. Robin Campbell, LMFT, PHD Many adults struggle with intense emotions, relationship conflict, self injury, substance dependence, or negative thoughts that affect day to day life.
New Hope Health offers client-centered services. Reach out for a confidential consultation and see exactly how we'd apply these strategies to your facility.
